University of Maryland Eye Associates at Redwood
Baltimore, Maryland, 21201, United States
Location status: Recruiting
Location contact
Osamah Saeedi, MD, MS
CONTACT
NCT Number: NCT05726058
The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.
The main question it aims to answer are:
* Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring?
Participants will be
* measured for their blood pressure, heart rate, height, and weight * dilated with tropicamide * imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry * imaged using the XyCAM RI while inhaling 100% oxygen through a mask
Interested in participating?
Request Info18 year–88 year
All sexes
Interventional
Not applicable
Baltimore, Maryland, 21201, United States
Location status: Recruiting
Osamah Saeedi, MD, MS
CONTACT
The investigators will capture images of the participant's retina using the XyCAM RI or XyCAM FC ("test data") and by color fundus photography, optical coherence tomography (OCT), and standard automated perimetry (SAP) - the "standard clinical data". The investigators will perform five tests. The first two tests will be conducted using the XyCAM RI or XyCAM FC to obtain "test data". The final two tests will be conducted using routine clinical instruments to obtain "standard clinical data". The investigators will administer eye drops (Tropicamide) to dilate the participant's pupils prior to the first test. Tropicamide is a chemical that causes pupil dilation and is commonly used by doctors to examine the participant's eyes. The entire set of test data sessions should last less than eighty (80) minutes with an additional 60 minutes for carrying out the necessary procedures and imaging using the standard clinical data.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
Time frame: through study completion, an average of 1 year
Dynamic video of ocular blood flow
Contact information is provided by the study sponsor or research team.
University of Maryland, Baltimore
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03011541
Abnormalities, Multiple, Age-Related Macular Degeneration
Westport, Connecticut, United States
View Trial DetailsNCT06943599
Age Related Macular Degeneration, Behavior
San Francisco, California, United States
View Trial DetailsNCT04232982
Cornea Disease, Corneal Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT06841575
Cranial Nerve Diseases, Eye Diseases
Durham, North Carolina, United States
View Trial Details